Real-World Study of Overall Survival in Patients with Stage III Non-Small Cell Lung Cancer Treated with Chemoradiotherapy with or without Durvalumab and an Exploratory Analysis of Effective Radiation Dose to the Immune Cells

N. Kishi, Y. Matsuo, M. Ogura,M. Kokubo,N. Araki, K. Fujii, S. Okumura,K. Nakamatsu,T. Kishi,T. Atsuta, T. Sakamoto,S. Otsu, T. Katagiri,M. Narabayashi,S. Fujishiro,Y. Iizuka,H. Ozasa,T. Hirai,T. Mizowaki

International journal of radiation oncology, biology, physics（2023）

引用 0|浏览7

暂无评分

摘要

Our real-world data in Japan showed that there was no significant difference in OS between the CCRT+D cohort and the CCRT cohort. High EDIC could be a risk for poor OS in patients treated with CCRT and consolidation durvalumab compared with those treated with CCRT.

查看译文

关键词

lung cancer,chemoradiotherapy,effective radiation dose,durvalumab,real-world,non-small

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要